Sleep is actually four different problems. Most people treat it like one thing, throw melatonin at it, and wonder why they still wake up wrecked. The first is low growth hormone during sleep. Your body releases most of its GH in the first couple hours of deep sleep, and if that pulse isn't firing right, you're not actually recovering. Ipamorelin works through ghrelin receptor signaling to directly promote slow-wave sleep — a 2002 study in the American Journal of Physiology confirmed this in humans. Second is the racing mind. Brain won't stop, you just can't fall asleep. DSIP (delta sleep-inducing peptide) is what's being researched here. Human trials including a double-blind study in chronic insomniacs showed better sleep efficiency and faster sleep onset. Third is "tired but wired." Completely depleted but can't settle. This usually points to mitochondrial dysfunction. SS-31 targets cardiolipin in the inner mitochondrial membrane — the FDA cleared it for Barth syndrome in 2025 and the fatigue data from those trials was solid. Fourth is broken circadian rhythm. You fall asleep fine but wake up at 3am. Epitalon works on the pineal gland to drive melatonin production through the enzyme pathway. Brunel University London confirmed the telomerase findings independently in 2025. Here's what I see people getting wrong: they buy all four and run them together. You won't know what worked. Most people have one or two dominant patterns. Figure out which one fits you first. Which of the four patterns sounds like you? Drop it below — this community has people who've worked through all of them. *This is Not medical advice, Not your doctor. Please also Do your own research.

BPC-157 doesn't get the hype it deserves. Most people in this space are chasing the flashy stuff — the GH secretagogues, the nootropic stacks, the fat loss peptides. And those all have their place. But BPC-157 is the one I reach for when something is actually broken. Injury. Gut issues. Tendon pain that's been dragging on for months. It works. Here's what the research shows: BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in gastric juice. It was originally studied for gut protection — and it does that genuinely well. But it's also one of the most consistent tissue repair compounds I've come across, with animal studies showing accelerated healing of tendons, ligaments, muscle tears, and even bone. The mechanisms are real: it upregulates growth factor signaling, promotes angiogenesis (new blood vessel formation), and reduces neuroinflammation. The healing timeline you see in rodent models typically breaks down like this — angiogenesis in the first phase, fibroblast proliferation in the second, and full tissue remodeling in the third. HOW I DOSE IT Standard protocol: 250-500mcg SubQ, once daily. I inject near the injury site when targeting something specific (shoulder, knee), or in abdominal fat for systemic/gut effects. Reconstitution: - 5mg vial + 1mL BAC water = 5mg/mL 250mcg = draw to 5 IU | 500mcg = draw to 10 IU - 5mg vial + 2mL BAC water = 2.5mg/mL 250mcg = draw to 10 IU | 500mcg = draw to 20 IU I prefer the 2mL reconstitution — easier to measure accurately. WHAT I'VE NOTICED I ran BPC-157 for 8 weeks following a shoulder impingement that had been bothering me for nearly a year. By week 4, I had noticeably more range of motion. By week 8, it was essentially gone. Could be coincidence. But I've now run it three times for different issues and the pattern has been consistent. For gut health: I've found oral BPC-157 (sodium salt form) works better for GI issues specifically. SubQ is better for systemic and musculoskeletal use.

This is one of my favorites to suggest when you just have that stubborn fat or you are responding to the GLP-1. Most fat loss peptides come with trade-offs. GLP-1 agents cause muscle loss. Full HGH raises blood sugar and IGF-1. CJC/Ipamorelin stacks need careful timing and monitoring. AOD-9604 is one of the cleaner options in the space because it was specifically engineered to do one thing: burn fat — without touching your hormonal axis. WHAT IS IT? AOD-9604 is hGH fragment 176-191. Monash University in Australia isolated the portion of the HGH molecule responsible for lipolysis and built a standalone peptide from it. The key finding from their research: this fragment retains the fat-burning mechanism of growth hormone but does not bind to GH receptors in the liver or muscle. Practically, that means: No effect on blood glucose (confirmed across multiple clinical trials) No effect on IGF-1 No effect on natural GH production It reached Phase 3 clinical trials for obesity treatment. The program was discontinued for commercial reasons — not safety concerns. The safety data from those trials is genuinely solid. HOW IT WORKS AOD-9604 stimulates beta-3 adrenergic receptors on fat cells, triggering the breakdown of stored triglycerides into free fatty acids. The effect is amplified in a fasted state, which is why the standard protocol calls for a morning injection before eating. DOSING 5mg vial + 2.5mL BAC water = 2mg/mL (most common reconstitution) 250mcg = draw to 12.5 IU 300mcg = draw to 15 IU 500mcg = draw to 25 IU Standard dose: 300mcg SubQ in the morning, fasted. Wait 30-60 minutes before eating. Cycle: 12-16 weeks on, 4-6 weeks off. Stacks well with: MK-677 (for muscle preservation), BPC-157, or alongside GLP-1 agents to target fat more specifically while managing the muscle loss problem. BERRY’s EXPERIENCE “AOD-9604 doesn't feel like anything — there's no stimulant effect, no noticeable shift in energy or appetite. The results appear in the mirror over weeks. I ran it at 300mcg/day for 12 weeks combined with a moderate deficit and consistent training. Abdominal fat was the most visibly reduced area, which tracks with the clinical data showing preferential visceral fat loss.”

These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for retatrutide: > highest dose lost 28.3% of body weight in 80 wks > 70 lbs ave > 45% lost 30% or more of their body weight > 65% on the top dose no longer clinically obese Retatrutide is more dynamic than semaglutide and tirzepatide because it targets three receptors (GIP, GLP-1, and glucagon), versus one and two, respectively. Side effects, on the highest dose (12mg), were higher for retatrutide than tirzepatide (nausea and GI), with an 11.3% drop out rate. The lowest 4mg dose still delivered 19% loss with fewer dropouts than placebo.